Skip to main navigation

The personal health technology revolution - EY - Global

Progressions 2012

The personal health
technology revolution

  • Share
An increasing array of diagnostics will conduct real-time monitoring in our everyday lives.
   
  Eric
Dishman
  Intel Corporation
Intel Fellow and Global Director, Health Innovation



Over the next decade, as much as 50% of health care will shift from the hospital and clinic to the home and community. New technologies will drive in-home care, at-workplace care and in-car care — thereby improving prevention, detection, behavior change and caregiver support.

A wide range of personal health technologies are coming into their own — something we refer to as the consumerization of medical devices and the medicalization of consumer devices. We will increasingly conduct virtual visits with doctors, nurses and care coaches through our cell phones, tablets and laptops.

A lot of care can be done in quick snippets — 10 seconds of interaction with your doctor — and doesn't require a face-to-face visit. Cancer patients shouldn't be sent to germ-filled hospitals for chemotherapy. It would be far safer and cheaper for them to have home infusion, but the current system is not set up that way.

An increasing array of diagnostics will conduct real-time monitoring in our everyday lives. Sensors will look for changes in how we move to detect neurological risk. Tiny implantable devices will analyze blood chemistry in real time and let a doctor know if our drugs are not being metabolized correctly. Not so long ago, an ultrasound was an expensive device the size of a cart or a room.

Today, it's quickly becoming a cell-phone-sized device available to every primary care clinic. As the optics and technology improve, it could soon become just another app on a smartphone. In this future, we will no longer have to go to the diagnostics — the diagnostics will always be available to us.

Another game changer is personalized genomics. The cost of sequencing a genome has fallen from nearly US$100 million per genome a decade ago to below US$5,000 today. In a few years, I expect it to be essentially free. Some clinics will have access to genomic computing clusters building personalized models of their patients that doctors will use to design customized treatments. Clinicians will need decision-support tools to make sense of all this data and coordinate large patient populations.

Technology can play a key role in enabling behavioral change. At Intel, we've conducted numerous pilots and identified 12 patient segments based on their responsiveness to different technologies — cell phones, social media, etc. For instance, we got a group of seniors to dramatically increase their daily walking by combining social networking, smart pedometers, monitoring using smart televisions, and incentives they cared about (e.g., donating money to a preferred cause).

Financial incentives and public policy are starting to catch up. At Intel, we track health reform in 22 countries, and we see a global trend toward collective payment — paying groups of providers to manage the health of a population based on value rather than volume of procedures. This will take a decade or so to play out, but it's a game changer.

New roles and business models

These changes will require new roles and business models for everyone. Patients and informal caregivers will need to be educated to empower more remote care and self care, and information technology and decision-support tools can play a critical role here.

Hospitals will no longer have a business model based on filling as many hospital beds as possible. Instead, they will have fewer beds and develop ancillary services in the community to enable a networked continuum of care.

Rather than being segmented by disease categories, medtech will likely reorganize into in-home or in-community technology platforms that can serve multiple disease states. Pharma companies may acquire new capabilities — software, IT, service delivery — and become brokers delivering a wide range of care services around a particular disease state and drug.

These changes will not be easy. Revolutions seldom are. But they promise a vastly improved future — a health care system with better quality, increased access and lower costs.

This article was featured in our report Progressions 2012 - the third place: health care everywhere.

RHS Navigation

Progressions 2012: health care everywhere
Progressions 2012: health care everywhere
Disruptive innovations and unsustainable costs are propelling life sciences companies into the behavioral change business. Learn why in our annual life sciences report.

See the bottom section of the main page for links to related columns from industry leaders.

Contact us

Back to top